Medicaid coverage for nonsteroidal topical atopic dermatitis treatment is often restrictive and variable across the United States
Published: 16 February 2024| Version 1 | DOI: 10.17632/rky67kt6g9.1
Contributors:
Eun Jae Kim, , John Barbieri, Description
Supplemental table for study investigating nonsteroidal topical AD medication coverage in the United States under Medicaid plans.
Files
Categories
Ruxolitinib, Atopic Dermatitis, Topical Treatment, Pimecrolimus, Tacrolimus, Health Insurance Coverage